Dr. Moe has 20+ years industrial experience having held senior management positions in product development working on international teams in both early and late stage diagnostic, biotechnology and biopharmaceutical companies including Gene-Trak/Amoco Technology Ventures/Vysis, bioMerieux, and Mosaic Technologies. Prior to founding Oligomerix, he was Director of Product Development at Pyrosequencing, Senior Molecular Biologist at Spire Biomedical, and Director of Product Development at Q-RNA, Inc. Dr. Moe received his Ph.D. degree in Molecular Biology/Molecular Biophysics from Wesleyan University, did his postdoctoral studies at Vanderbilt University in the Center for Molecular Toxicology where he was jointly appointed in the Biochemistry Department in the Medical School, and the Chemistry Department in the College of Arts and Sciences, and has an MBA degree with a concentration in entrepreneurial studies from Boston University.

Eliot J. Davidowitz, Ph.D. Chief Scientist, Co-Founder

Dr. Davidowitz has 20+ years of experience in academic and industrial research and development. Prior to founding Oligomerix, he was a Senior Scientist and Laboratory Manager at Q-RNA, Inc. Dr. Davidowitz received his B.S. from Cornell University, Ph.D. from Case Western Reserve University and completed an NIH postdoctoral fellowship at Albert Einstein College of Medicine. His academic work was in molecular and cellular biology and his industrial experience has focused on assay development for drug discovery targeting tau protein for Alzheimer’s disease.

Jack Pasini, MBA, Director, Chief Commercial Officer

Mr. Pasini is the former Pfizer Vice President Worldwide Marketing, Product Development and Business Intelligence and Planning. Prior to joining Oligomerix, Mr. Pasini spent 30 years at Pfizer, Inc. where he held multiple senior level positions and was responsible for some of the company’s most successful brands including Spiriva, Zithromax, Diflucan and Zyvox. Among his career highlights, Mr. Pasini served as Vice President of Pfizer’s Infectious Diseases, Allergy & Respiratory Therapeutic Groups, where he led commercial decision-making involving two key therapeutic areas, generating annual revenue in excess of $5 billion.